FINWIRES · TerminalLIVE
FINWIRES

Abivax's Obefazimod Trial Meets Main Goal in Ulcerative Colitis; Shares Fall After Hours

By

Abivax SA (ABVX) said its Phase 3 maintenance trial evaluating obefazimod in adults with moderately to severely active ulcerative colitis met its primary endpoint

Both the 25 mg and 50 mg doses also met all key secondary endpoints, including endoscopic improvement, endoscopic remission, corticosteroid-free clinical remission and sustained clinical remission, the company said Monday in a statement.

Obefazimod demonstrated a favorable safety profile over the 44-week maintenance trial, with no new safety signals observed, the company said.

Week-44 clinical remission rates were 50.8% with 25 mg and 51.3% with 50 mg, versus 10.4% for placebo, the company said.

Abivax plans to submit a New Drug Application to the US Food and Drug Administration in Q4.

Abivax shares fell 23% in after-hours trading.

Related Articles

Wire

Hewlett Packard Enterprise Fiscal Q2 Adjusted Earnings, Revenue Rise; Shares Surge After Hours

Hewlett Packard Enterprise (HPE) reported fiscal Q2 adjusted earnings late Monday of $0.79 per diluted share, up from $0.38 a year earlier.Analysts polled by FactSet expected $0.53.Revenue in the three months ended April 30 rose to $10.7 billion from $7.63 billion a year earlier.Analysts surveyed by FactSet expected $9.78 billion.Hewlett Packard Enterprise expects Q3 adjusted EPS of $0.88 to $0.93 on revenue of $11.5 billion to $12.1 billion.Analysts polled by FactSet expect adjusted EPS of $0.58 on revenue of $10.9 billion.The company boosted full-year adjusted EPS guidance to $3.35 to $3.45 from the prior range of $2.30 to $2.50.Analysts polled by FactSet project $2.42.Hewlett Packard Enterprise shares surged 31% in after-hours trading.

$HPE
Wire

Credo Technology Fiscal Q4 Adjusted Earnings, Revenue Rise; Shares Fall After Hours

Credo Technology (CRDO) reported fiscal Q4 adjusted earnings late Monday of $1.16 per diluted share, up from $0.35 a year earlier.Analysts polled by FactSet expected $1.02.Revenue in the three months ended May 2 rose to $437 million from $170 million a year earlier.Analysts surveyed by FactSet expected $431.8 million.The company expects Q1 revenue of $465 million to $475 million. Analysts expect $461.3 million.Credo shares fell 15% in after-hours trading.

$CRDO
Wire

Digital Brands Group Expands GCC Deal, Receives First Orders Under $125 Million U.S. Program

Digital Brands Group (DBGI) has received initial purchase orders for its $125 million U.S. program and announced an expanded partnership with GCC, the company said Monday.The partnership adds new apparel and soft goods revenue opportunities through GCC's digital networks, physical installations, and domestic and international events and hospitality, the company said.Digital Brands Group's CEO Hil Davis said the additional revenue opportunities are new and incremental to the company's guidance issued last month, calling the expansion a "broader opportunity."Price: $0.81, Change: $+0.32, Percent Change: +66.79%

$DBGI